- Home
- ESPR vs DHIL Comparison
ESPR vs DHIL Comparison
Compare ESPR & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- DHIL
- Stock Information
- Founded
- ESPR 2008
- DHIL 1990
- Country
- ESPR United States
- DHIL United States
- Employees
- ESPR N/A
- DHIL N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- DHIL Investment Managers
- Sector
- ESPR Health Care
- DHIL Finance
- Exchange
- ESPR Nasdaq
- DHIL Nasdaq
- Market Cap
- ESPR 445.6M
- DHIL 392.1M
- IPO Year
- ESPR 2013
- DHIL 1995
- Fundamental
- Price
- ESPR $2.82
- DHIL $144.96
- Analyst Decision
- ESPR Buy
- DHIL
- Analyst Count
- ESPR 6
- DHIL 0
- Target Price
- ESPR $6.50
- DHIL N/A
- AVG Volume (30 Days)
- ESPR 6.1M
- DHIL 24.7K
- Earning Date
- ESPR 11-06-2025
- DHIL 11-03-2025
- Dividend Yield
- ESPR N/A
- DHIL 4.22%
- EPS Growth
- ESPR N/A
- DHIL 21.42
- EPS
- ESPR N/A
- DHIL 17.58
- Revenue
- ESPR $268,125,000.00
- DHIL $151,281,009.00
- Revenue This Year
- ESPR $10.59
- DHIL N/A
- Revenue Next Year
- ESPR N/A
- DHIL N/A
- P/E Ratio
- ESPR N/A
- DHIL $8.09
- Revenue Growth
- ESPR N/A
- DHIL 6.29
- 52 Week Low
- ESPR $0.69
- DHIL $122.32
- 52 Week High
- ESPR $3.94
- DHIL $173.25
- Technical
- Relative Strength Index (RSI)
- ESPR 78.99
- DHIL 51.01
- Support Level
- ESPR $2.37
- DHIL $139.13
- Resistance Level
- ESPR $2.73
- DHIL $145.76
- Average True Range (ATR)
- ESPR 0.16
- DHIL 2.06
- MACD
- ESPR 0.02
- DHIL -0.00
- Stochastic Oscillator
- ESPR 99.32
- DHIL 57.50
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.